The simple urine test correctly identified bladder cancer-associated genes in 71 of 77 patients who went on to develop a ...

Natera’s Signatera test receives Japan’ PMDA approval as a companion diagnostic in muscle-invasive bladder cancer: Austin, Texas Friday, September 25, 2026, 17:00 Hrs [IST] Na ...

A non-invasive urine test could speed up diagnosis of bladder cancer, an NHS study has found. Trials of the GALEAS urine bladder test across seven NHS sites found it discovered nine in ten patients ...

A new study has found that the use of a specific at-home urine test could detect bladder cancer with accuracy. Here are its implications and why this test is a medical breakthrough.

Bladder cancer is a common urinary tract cancer that can be difficult to detect early because its symptoms often overlap with less serious conditions. Earlier identification could improve treatment ...

Natera (NTRA) said Tuesday that Japan's Pharmaceuticals and Medical Devices Agency has approved the company's Signatera test as a companion diagnostic for muscle-invasive bladder ...

Bladder cancer detection could get easier, faster and much less invasive as a new urine test can help identify it. According to new UK research, patients may not have to wait for an invasive bladder ...

A SIMPLE urine test can detect nine out of ten bladder cancers, according to results from an NHS trial. It could be done at home and save tens of thousands of patients per year from the discomfort ...

A high percentage of bladder cancers can be cured if they are found early. Once cancer spreads outside the bladder, it is much harder to treat. That’s why it’s important to first bring up any ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

AUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals ...

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...